European Medicines Agency Validates Kite’s Marketing Application for Company’s Second CAR T Cell…
Kite, a Gilead Company announced that the company’s Marketing Authorization Application (MAA) for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the…
Read More...
Read More...
